ArticleBlood2022
iPLAT1: the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study.
Abstract readClinical Trial, Phase I
In one paragraph
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Quality control and non-clinical testing of iPSC- and ESC-derived medicinal products: A systematic review.Stem cell reports · 2026Pooled it
- Proteomics of heterogeneous megakaryocytes identifies JI051 as an enhancer of platelet biogenesis.Life science alliance · 2026Article
- Induced pluripotent stem cells from discovery to translation.Nature medicine · 2026Review
- First evidence of the circulation of induced pluripotent stem cell-derived platelets in humans.Stem cells translational medicine · 2026Article
- Efficient chemical reprogramming of human T cells into functional megakaryocytes and platelets.Science advances · 2026Article
- Laboratory Assessment and Clinical Outlook forAnnals of laboratory medicine · 2026Review
- Temporal Lysophosphatidic Acid Supplementation Enhances Megakaryocyte Differentiation and Platelet Production From Human Hematopoietic Progenitors.Cell biology international · 2026Article
- Engineering platelets as cancer therapeutics.Nature reviews. Clinical oncology · 2026Review
- Article
- Optimizing the Method for Differentiation of Functional Platelets from Human Induced Pluripotent Stem Cells.Stem cell reviews and reports · 2026Article
- Functional xenogeneic hematopoietic cells maintaining donor-dominant identity and immune tolerance enable therapy.Experimental hematology & oncology · 2026Article
- The Kifc3 Motor Protein Controls Centrosomal Factor Cep192 in Ontogenic Coordination of Megakaryocyte Development.bioRxiv : the preprint server for biology · 2026Article
- Redox Regulation of Megakaryocyte Differentiation and Platelet Biogenesis.Antioxidants (Basel, Switzerland) · 2026Review
- Induced pluripotent stem cell-derived platelets kill multidrug-resistantResearch and practice in thrombosis and haemostasis · 2026Article
- Induction of moderate DNA damage enhances megakaryopoiesis and platelet production.Blood advances · 2026Article
- Collagen nanofiber reinforced alginate hydrogel tube microbioreactors for cell culture.Frontiers in bioengineering and biotechnology · 2026Article
- Modeling myeloid cell development in health and disease using induced pluripotent stem cells.Frontiers in immunology · 2026Review
- Aging-dependent reduction of KAT7/HBO1 activity impairs imMKCL-based platelet production by promoting immune properties.Stem cell reports · 2025Article
- Application potential of induced pluripotent stem cells in the research and treatment of autoimmune diseases (Review).Molecular medicine reports · 2025Review
- Platelet Transfusion for Patients with Cancer: An Update.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025Review
Corrections and comments
- Commented on by
Authors and funding
26 authors at 5 institutions in 1 country.
Naoshi SugimotoDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.ORCID 0000-0002-7271-9175
Junya KandaDepartment of Hematology, Kyoto University Hospital, Kyoto, Japan.ORCID 0000-0002-6704-3633
Sou NakamuraDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.ORCID 0000-0002-5601-9777
Toshiyuki KitanoDepartment of Hematology, Kyoto University Hospital, Kyoto, Japan.
Masakatsu HishizawaDepartment of Hematology, Kyoto University Hospital, Kyoto, Japan.
Tadakazu KondoDepartment of Hematology, Kyoto University Hospital, Kyoto, Japan.ORCID 0000-0002-8959-6271
Shin ShimizuDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Akiko ShigemasaDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Hideyo HiraiDepartment of Clinical Laboratory Medicine, Kyoto University Hospital, Kyoto, Japan.
Yasuyuki AraiDepartment of Clinical Laboratory Medicine, Kyoto University Hospital, Kyoto, Japan.ORCID 0000-0002-9662-5093
Manabu MinamiInstitute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan.ORCID 0000-0003-0052-398X
Harue TadaInstitute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan.
Dai MomoseDepartment of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan.
Ki-Ryang KohDepartment of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan.
Masayuki NogawaCentral Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.ORCID 0000-0002-4835-2545
Naohide WatanabeDivision of Hematology, Keio University School of Medicine, Tokyo, Japan.
Shinichiro OkamotoDivision of Hematology, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0002-6257-4152
Makoto HandaCenter for Transfusion Medicine & Cell Therapy, Keio University School of Medicine, Tokyo, Japan.
Akira SawaguchiDepartment of Anatomy, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Nobuki MatsuyamaJapanese Red Cross Kinki Block Blood Center, Osaka, Japan.
Mitsunobu TanakaJapanese Red Cross Kinki Block Blood Center, Osaka, Japan.ORCID 0000-0002-9024-6818
Tomoya HayashiJapanese Red Cross Kinki Block Blood Center, Osaka, Japan.ORCID 0000-0002-1776-0052
Akihiro FuchizakiJapanese Red Cross Kinki Block Blood Center, Osaka, Japan.ORCID 0000-0003-3387-1817
Yoshihiko TaniJapanese Red Cross Kinki Block Blood Center, Osaka, Japan.
Akifumi Takaori-KondoDepartment of Hematology, Kyoto University Hospital, Kyoto, Japan.ORCID 0000-0001-7678-4284
Koji EtoDepartment of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.ORCID 0000-0002-5863-7122
Kyoto University Hospital · JPJapanese Red Cross Society, Japan · JPKyoto University · JPKeio University · JPUniversity of Miyazaki · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Blood PlateletsInduced Pluripotent Stem CellsHumansPlateletpheresisPlatelet Transfusion
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.